<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection>
  <source>PubTator</source>
  <date>2017-12-04</date>
  <key>BioC.key</key>
  <document>
    <id>10077651</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Mechanism of increased iron absorption in murine model of hereditary hemochromatosis : increased duodenal expression of the iron transporter DMT1.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006432</infon>
        <infon key="type">Disease</infon>
        <location offset="58" length="26"/>
        <text>hereditary hemochromatosis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>147</offset>
      <text>Hereditary hemochromatosis (HH) is a common autosomal recessive disorder characterized by tissue iron deposition secondary to excessive dietary iron absorption. We recently reported that HFE, the protein defective in HH, was physically associated with the transferrin receptor (TfR) in duodenal crypt cells and proposed that mutations in HFE attenuate the uptake of transferrin-bound iron from plasma by duodenal crypt cells, leading to up-regulation of transporters for dietary iron. Here, we tested the hypothesis that HFE-/- mice have increased duodenal expression of the divalent metal transporter (DMT1). By 4 weeks of age, the HFE-/- mice demonstrated iron loading when compared with HFE +/+ littermates, with elevated transferrin saturations (68. 4% vs. 49. 8%) and elevated liver iron concentrations (985 micrograms vs. 381 micrograms). By using Northern blot analyses, we quantitated duodenal expression of both classes of DMT1 transcripts  one containing an iron responsive element (IRE), called DMT1 (IRE), and one containing no IRE, called DMT1 (non-IRE). The positive control for DMT1 up-regulation was a murine model of dietary iron deficiency that demonstrated greatly increased levels of duodenal DMT1 (IRE) mRNA. HFE-/- mice also demonstrated an increase in duodenal DMT1 (IRE) mRNA (average 7. 7-fold), despite their elevated transferrin saturation and hepatic iron content. Duodenal expression of DMT1 (non-IRE) was not increased, nor was hepatic expression of DMT1 increased. These data support the model for HH in which HFE mutations lead to inappropriately low crypt cell iron, with resultant stabilization of DMT1 (IRE) mRNA, up-regulation of DMT1, and increased absorption of dietary iron.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D006432</infon>
        <infon key="type">Disease</infon>
        <location offset="147" length="26"/>
        <text>Hereditary hemochromatosis</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D006432</infon>
        <infon key="type">Disease</infon>
        <location offset="175" length="2"/>
        <text>HH</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D030342</infon>
        <infon key="type">Disease</infon>
        <location offset="191" length="28"/>
        <text>autosomal recessive disorder</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D006432</infon>
        <infon key="type">Disease</infon>
        <location offset="364" length="2"/>
        <text>HH</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D018798</infon>
        <infon key="type">Disease</infon>
        <location offset="1281" length="23"/>
        <text>dietary iron deficiency</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10441573</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="59" length="13"/>
        <text>breast cancer</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="77" length="14"/>
        <text>ovarian cancer</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>93</offset>
      <text>For genetic counseling and predictive testing in families with inherited breast-ovarian cancer, penetrances and expressions of the underlying mutations should be known. We have previously reported two BRCA1 founder mutations in the Norwegian population. Index cases for the present study were found two different ways  through a series of consecutive ovarian cancers (n = 16) and through our family cancer clinic (n = 14). Altogether, 20 of the patients had BRCA1 1675delA, and 10 had 1135insA. Their relatives were described with respect to absence/presence of breast and/or ovarian cancer. Of 133 living female relatives, 83 (62%) were tested for the presence of a mutation. No difference, in penetrance and expression, between the two mutations were found, whereas differences according to method of ascertainment were seen. The overall findings were that disease started to occur at age 30 years and that by age 50 years 48% of the mutation-carrying women had experienced breast and/or ovarian cancer. More ovarian cancers than breast cancers were recorded. Both penetrance and expression (breast cancer vs. ovarian cancer) were different from those in reports of the Ashkenazi founder mutations. Whether the reported differences reflect true differences and/or methodological problems is discussed. An observed excess of mutation carriers could not be accounted for by methodological problems; possible explanations were a " true " low penetrance or preferential segregation.. </text>
      <annotation id="2">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="156" length="31"/>
        <text>inherited breast-ovarian cancer</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="444" length="15"/>
        <text>ovarian cancers</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="492" length="6"/>
        <text>cancer</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D001943|D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="655" length="28"/>
        <text>breast and/or ovarian cancer</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D001943|D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="1069" length="28"/>
        <text>breast and/or ovarian cancer</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="1104" length="15"/>
        <text>ovarian cancers</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="1125" length="14"/>
        <text>breast cancers</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="1187" length="13"/>
        <text>breast cancer</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="1205" length="14"/>
        <text>ovarian cancer</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10426999</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>85</offset>
      <text>BRCA1 encodes a tumor suppressor that is mutated in familial breast and ovarian cancers. Here, it is shown that BRCA1 interacts in vitro and in vivo with hRad50, which forms a complex with hMre11 and p95/nibrin. Upon irradiation, BRCA1 was detected in discrete foci in the nucleus, which colocalize with hRad50. Formation of irradiation-induced foci positive for BRCA1, hRad50, hMre11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wild-type BRCA1. Ectopic expression of wild-type, but not mutated, BRCA1 in these cells rendered them less sensitive to the DNA damage agent, methyl methanesulfonate. These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the hRad50-hMre11-p95 complex.. </text>
      <annotation id="0">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="101" length="5"/>
        <text>tumor</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="137" length="35"/>
        <text>familial breast and ovarian cancers</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="515" length="13"/>
        <text>breast cancer</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10480214</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Early onset of X-linked Emery-Dreifuss muscular dystrophy in a boy with emerin gene deletion.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D020389</infon>
        <infon key="type">Disease</infon>
        <location offset="15" length="42"/>
        <text>X-linked Emery-Dreifuss muscular dystrophy</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>94</offset>
      <text>A boy developed contractures of the Achilles tendons at 3 years and of the postcervical muscles at 7 years, although neither contractures of the elbows nor cardiac abnormality were recognized by the age of 9 years. Muscle computed tomography scanning revealed changes characteristic of muscle involvement. Emerin was not detected in the biopsied muscle, and RT-PCR and PCR-based genomic DNA analyses of the emerin gene demonstrated no amplification product in the patient. These results confirmed the diagnosis of X-linked Emery-Dreifuss muscular dystrophy (EDMD), and reinforce the necessity of molecular genetic diagnosis of the membrane protein emerin in younger patients with possible EDMD before appearance of the typical symptoms, to avoid sudden cardiac death.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D003286</infon>
        <infon key="type">Disease</infon>
        <location offset="110" length="36"/>
        <text>contractures of the Achilles tendons</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D003286</infon>
        <infon key="type">Disease</infon>
        <location offset="219" length="26"/>
        <text>contractures of the elbows</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D018376</infon>
        <infon key="type">Disease</infon>
        <location offset="250" length="19"/>
        <text>cardiac abnormality</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D020389</infon>
        <infon key="type">Disease</infon>
        <location offset="608" length="42"/>
        <text>X-linked Emery-Dreifuss muscular dystrophy</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D020389</infon>
        <infon key="type">Disease</infon>
        <location offset="652" length="4"/>
        <text>EDMD</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D020389</infon>
        <infon key="type">Disease</infon>
        <location offset="783" length="4"/>
        <text>EDMD</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D016757</infon>
        <infon key="type">Disease</infon>
        <location offset="840" length="20"/>
        <text>sudden cardiac death</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10712201</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Identification of novel imprinted transcripts in the Prader-Willi syndrome and Angelman syndrome deletion region: further evidence for regional imprinting control.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="53" length="21"/>
        <text>Prader-Willi syndrome</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D017204</infon>
        <infon key="type">Disease</infon>
        <location offset="79" length="17"/>
        <text>Angelman syndrome</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>164</offset>
      <text>Deletions and other abnormalities of human chromosome 15q11-q13 are associated with two developmental disorders, Prader-Willi syndrome (PWS) and Angelman syndrome (AS). Loss of expression of imprinted, paternally expressed genes has been implicated in PWS. However, the number of imprinted genes that contribute to PWS, and the range over which the imprinting signal acts to silence one copy of the gene in a parent-of-origin-specific manner, are unknown. To identify additional imprinted genes that could contribute to the PWS phenotype and to understand the regional control of imprinting in 15q11-q13, we have constructed an imprinted transcript map of the PWS-AS deletion interval. The imprinting status of 22 expressed sequence tags derived from the radiation-hybrid human transcript maps or physical maps was determined in a reverse transcriptase-PCR assay and correlated with the position of the transcripts on the physical map. Seven new paternally expressed transcripts localize to an approximately 1. 5-Mb domain surrounding the SNRPN-associated imprinting center, which already includes four imprinted, paternally expressed genes. All other tested new transcripts in the deletion region were expressed from both alleles. A domain of exclusive paternal expression surrounding the imprinting center suggests strong regional control of the imprinting process. This study provides the means for further investigation of additional genes that cause or modify the phenotypes associated with rearrangements of 15q11-q13. </text>
      <annotation id="2">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="277" length="21"/>
        <text>Prader-Willi syndrome</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="300" length="3"/>
        <text>PWS</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D017204</infon>
        <infon key="type">Disease</infon>
        <location offset="309" length="17"/>
        <text>Angelman syndrome</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D017204</infon>
        <infon key="type">Disease</infon>
        <location offset="328" length="2"/>
        <text>AS</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="416" length="3"/>
        <text>PWS</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="479" length="3"/>
        <text>PWS</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D011218</infon>
        <infon key="type">Disease</infon>
        <location offset="688" length="3"/>
        <text>PWS</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10818206</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Isolation, genomic organization, and expression analysis of the mouse and rat homologs of MEFV, the gene for familial mediterranean fever.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D010505</infon>
        <infon key="type">Disease</infon>
        <location offset="109" length="28"/>
        <text>familial mediterranean fever</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>139</offset>
      <text>Familial Mediterranean fever (FMF) is a recessive disorder characterized by episodes of fever with serositis or synovitis. Recently the FMF gene (MEFV) was cloned; the protein product, pyrin/marenostrin, is thought to regulate inflammation in myeloid cells. In this manuscript we report the mouse and rat homologs of MEFV. The murine gene contains ten exons with a coding sequence of 2304 bp, while the rat homolog has nine exons with a coding sequence of 2253 bp. A considerable amino acid sequence homology was observed between the mouse and human (47. 6% identity and 65. 5% similarity) and between the mouse and rat genes (73. 5% identity and 82. 1% similarity). The predicted rodent proteins have several important domains and signals found in human pyrin, including a B-box zinc finger domain, Robbins-Dingwall nuclear localization signal, and coiled-coil domain. However, perhaps because of an ancient frame-shift mutation, neither the mouse nor the rat protein has an intact C-terminal B30. 2 domain, in which most FMF-associated mutations have been found in human MEFV. Nevertheless, like the human gene, mouse Mefv is expressed in peripheral blood granulocytes but not lymphocytes. Consistent with its expression in granulocytes, Mefv was detected at high levels in the primary follicles and marginal zones of the splenic white pulp. Mefv is localized on mouse Chromosome (Chr) 16, region A3-B1, extending a region of synteny with human Chr 16p13. 3. Development of knockout and knockin mouse models may provide further insights into the functional evolution of this gene. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D010505</infon>
        <infon key="type">Disease</infon>
        <location offset="139" length="28"/>
        <text>Familial Mediterranean fever</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D010505</infon>
        <infon key="type">Disease</infon>
        <location offset="169" length="3"/>
        <text>FMF</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D030342</infon>
        <infon key="type">Disease</infon>
        <location offset="179" length="18"/>
        <text>recessive disorder</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D005334</infon>
        <infon key="type">Disease</infon>
        <location offset="227" length="5"/>
        <text>fever</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D012700</infon>
        <infon key="type">Disease</infon>
        <location offset="238" length="9"/>
        <text>serositis</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D013585</infon>
        <infon key="type">Disease</infon>
        <location offset="251" length="9"/>
        <text>synovitis</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D010505</infon>
        <infon key="type">Disease</infon>
        <location offset="275" length="3"/>
        <text>FMF</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D010505</infon>
        <infon key="type">Disease</infon>
        <location offset="1162" length="3"/>
        <text>FMF</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10878391</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="40" length="24"/>
        <text>Wiskott-Aldrich syndrome</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="96" length="24"/>
        <text>Wiskott-Aldrich syndrome</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>179</offset>
      <text>The Wiskott-Aldrich syndrome (WAS) is caused by defects in the WAS protein (WASP) gene on the X chromosome. Previous study disclosed that flow cytometric analysis of intracellular WASP expression (FCM-WASP analysis) in lymphocytes was useful for the diagnosis of WAS patients. Lymphocytes from all WAS patients showed WASPdim instead of WASPbright. Here we report that FCM-WASP analysis in monocytes could be a useful tool for the WAS carrier diagnosis. Monocytes from all nine WAS carriers showed varied population of WASPdim together with WASPbright. None of control individuals possessed the WASPdim population. In contrast, lymphocytes from all the carriers except two lacked the WASPdim population. The difference of the WASPdim population in monocytes and lymphocytes observed in WAS carriers suggests that WASP plays a more critical role in the development of lymphocytes than in that of monocytes. The present studies suggest that a skewed X-chromosomal inactivation pattern observed in WAS carrier peripheral blood cells is not fixed at the hemopoietic stem cell level but progresses after the lineage commitment.. </text>
      <annotation id="2">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="183" length="24"/>
        <text>Wiskott-Aldrich syndrome</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="209" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="242" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="442" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="477" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="610" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="657" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="965" length="3"/>
        <text>WAS</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D014923</infon>
        <infon key="type">Disease</infon>
        <location offset="1174" length="3"/>
        <text>WAS</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>1301201</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>In vitro and in vivo correlations for I65T and M1V mutations at the phenylalanine hydroxylase locus.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>101</offset>
      <text>Mutations at the phenylalanine hydroxylase (PAH) locus are the major cause of hyperphenylalaninemia. We have previously described four mutations (M1V, IVS12nt1, R408W, and S349P) at the PAH locus in French Canadians with ancestry in eastern Quebec. Here we report (1) identification of another mutation, on a haplotype 9 chromosome, which converts codon 65 from isoleucine (ATT) to threonine (ACT), (2) expression analysis of the I65T mutation in COS cells demonstrating 75% loss of both immunoreactive protein and enzyme activity, and (3) expression analysis of the most prevalent PKU allele (M1V) in eastern Quebec, showing nondetectable levels of PAH protein and activity, a finding compatible with a mutation in the translation initiation codon. Homozygosity for M1V and codominant inheritance of I65T/R408W were both associated with classical phenylketonuria.. </text>
      <annotation id="0">
        <infon key="identifier">MESH:D010661</infon>
        <infon key="type">Disease</infon>
        <location offset="179" length="21"/>
        <text>hyperphenylalaninemia</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D010661</infon>
        <infon key="type">Disease</infon>
        <location offset="683" length="3"/>
        <text>PKU</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D010661</infon>
        <infon key="type">Disease</infon>
        <location offset="939" length="25"/>
        <text>classical phenylketonuria</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>1351034</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="29" length="3"/>
        <text>APC</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D018268</infon>
        <infon key="type">Disease</infon>
        <location offset="44" length="24"/>
        <text>adrenocortical carcinoma</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="89" length="30"/>
        <text>familial adenomatous polyposis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>121</offset>
      <text>Endocrine neoplasms have been reported occasionally in patients with familial adenomatous polyposis (FAP). An adrenocorotical carcinoma was studied in a patient with a family history of FAP. Loss of heterozygosity (LOH) in the region close to the adenomatous polyposis coli (APC) gene was detected in this carcinoma, and evidence was obtained that there was a loss of the normal allele of the APC gene. This is the first demonstration of LOH at the APC locus in adrenocortical tumors. The present results and our previous data on LOH in a recurring desmoid tumor suggest that the heterozygous mutant/wild-type condition of the APC gene may give rise to benign tumors, and that functional loss of this gene leads to development of tumors not only in the colon but also in other various parts of the body in FAP patients.. </text>
      <annotation id="3">
        <infon key="identifier">MESH:D004701</infon>
        <infon key="type">Disease</infon>
        <location offset="121" length="19"/>
        <text>Endocrine neoplasms</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="190" length="30"/>
        <text>familial adenomatous polyposis</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="222" length="3"/>
        <text>FAP</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D018268</infon>
        <infon key="type">Disease</infon>
        <location offset="231" length="25"/>
        <text>adrenocorotical carcinoma</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="307" length="3"/>
        <text>FAP</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="368" length="26"/>
        <text>adenomatous polyposis coli</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="396" length="3"/>
        <text>APC</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D002277</infon>
        <infon key="type">Disease</infon>
        <location offset="427" length="9"/>
        <text>carcinoma</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="514" length="3"/>
        <text>APC</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="570" length="3"/>
        <text>APC</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D018268</infon>
        <infon key="type">Disease</infon>
        <location offset="583" length="21"/>
        <text>adrenocortical tumors</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:C535944</infon>
        <infon key="type">Disease</infon>
        <location offset="670" length="13"/>
        <text>desmoid tumor</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="748" length="3"/>
        <text>APC</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="774" length="13"/>
        <text>benign tumors</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="851" length="6"/>
        <text>tumors</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D011125</infon>
        <infon key="type">Disease</infon>
        <location offset="927" length="3"/>
        <text>FAP</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>1384323</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="47" length="9"/>
        <text>Tay-Sachs</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>103</offset>
      <text>Deficiency of beta-hexosaminidase A (Hex A) activity typically results in Tay-Sachs disease. However, healthy subjects found to be deficient in Hex A activity (i. e., pseudodeficient) by means of in vitro biochemical tests have been described. We analyzed the HEXA gene of one pseudodeficient subject and identified both a C739-to-T substitution that changes Arg247----Trp on one allele and a previously identified Tay-Sachs disease mutation on the second allele. Six additional pseudodeficient subjects were found to have the C739-to-T mutation. This allele accounted for 32% (20/62) of non-Jewish enzyme-defined Tay-Sachs disease carriers but for none of 36 Jewish enzyme-defined carriers who did not have one of three known mutations common to this group. The C739-to-T allele, together with a " true " Tay-Sachs disease allele, causes Hex A pseudodeficiency. Given both the large proportion of non-Jewish carriers with this allele and that standard biochemical screening cannot differentiate between heterozygotes for the C739-to-T mutations and Tay-Sachs disease carriers, DNA testing for this mutation in at-risk couples is essential. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="103" length="35"/>
        <text>Deficiency of beta-hexosaminidase A</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="177" length="17"/>
        <text>Tay-Sachs disease</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="234" length="18"/>
        <text>deficient in Hex A</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="518" length="17"/>
        <text>Tay-Sachs disease</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="717" length="17"/>
        <text>Tay-Sachs disease</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="909" length="17"/>
        <text>Tay-Sachs disease</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D013661</infon>
        <infon key="type">Disease</infon>
        <location offset="1153" length="17"/>
        <text>Tay-Sachs disease</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>1671851</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Linkage analysis in X-linked adrenoleukodystrophy and application in post- and prenatal diagnosis.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="20" length="29"/>
        <text>X-linked adrenoleukodystrophy</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>99</offset>
      <text>We have performed linkage analysis with the DNA markers DXS52 and the clotting factor VIII gene (F8C), in several large families with X-linked adrenoleukodystrophy (ALD). The tight linkage to DXS52 could be extended giving a maximal LOD score of 22. 5 at 1 cM. F8C was also tightly linked to ALD with a maximal LOD score of 7. 8 without recombination. Multipoint linkage analysis with the markers DXS304, DXS52, and F8C indicated that both the gene for ALD and for F8C are distal to DXS52. In four patients with ALD, no major structural rearrangement in the Xqter region was observed; in particular, there were no abnormalities in the vision blindness genes. DNA analysis appeared to be of use in determination of the carrier status of females at risk, for the determination of the origin of the mutation in a particular family, and for prenatal diagnosis.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="233" length="29"/>
        <text>X-linked adrenoleukodystrophy</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="264" length="3"/>
        <text>ALD</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="391" length="3"/>
        <text>ALD</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="552" length="3"/>
        <text>ALD</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D000326</infon>
        <infon key="type">Disease</infon>
        <location offset="611" length="3"/>
        <text>ALD</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D003117</infon>
        <infon key="type">Disease</infon>
        <location offset="713" length="43"/>
        <text>abnormalities in the vision blindness genes</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2562820</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Linkage analysis of the apolipoprotein C2 gene and myotonic dystrophy on human chromosome 19 reveals linkage disequilibrium in a French-Canadian population.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009223</infon>
        <infon key="type">Disease</infon>
        <location offset="51" length="18"/>
        <text>myotonic dystrophy</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>157</offset>
      <text>The gene for human apolipoprotein C2 (APOC2), situated on the proximal long arm of chromosome 19, is closely linked to the gene for the most common form of adult muscular dystrophy, myotonic dystrophy (DM). Six APOC2 RFLPs (TaqI, BglI, BanI, BamHI, NcoI, and AvaII) have been identified to date. We have conducted a comprehensive DM linkage study utilizing all six RFLPs and involving 50 families and 372 individuals. The most informative RFLPs are, in descending order, NcoI (lod = 6. 64, theta = 0. 05), BglI (lod = 6. 12, theta = 0. 05), AvaII (lod = 6. 02, theta = 0. 03), BanI (lod = 5. 76, theta = 0. 04), TaqI (lod = 4. 29, theta = 0. 06), and BamHI (lod = 1. 75, theta = 0. 01). A substantial increase in the lod scores over those seen with the individual RFLPs was obtained when the linkage of the entire APOC2 haplotype (composed of the six RFLPs) was studied (lod = 17. 87, theta = 0. 04). We have observed significant inter-APOC2 RFLP linkage disequilibrium. Consequently, the three most informative RFLPs have been found to be BanI, TaqI, and either BglI, AvaII, or NcoI polymorphisms. We also demonstrate linkage disequilibrium between DM and APOC2 in our French-Canadian population (standardized disequilibrium constant phi =. 22, chi 2 = 5. 12, df = 1, P less than 0. 04). This represents the first evidence of linkage disequilibrium between APOC2 and the DM locus. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D009136</infon>
        <infon key="type">Disease</infon>
        <location offset="319" length="18"/>
        <text>muscular dystrophy</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D009223</infon>
        <infon key="type">Disease</infon>
        <location offset="339" length="18"/>
        <text>myotonic dystrophy</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D009223</infon>
        <infon key="type">Disease</infon>
        <location offset="359" length="2"/>
        <text>DM</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D009223</infon>
        <infon key="type">Disease</infon>
        <location offset="487" length="2"/>
        <text>DM</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D009223</infon>
        <infon key="type">Disease</infon>
        <location offset="1529" length="2"/>
        <text>DM</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3258663</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D014842</infon>
        <infon key="type">Disease</infon>
        <location offset="45" length="14"/>
        <text>von Willebrand</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D056729</infon>
        <infon key="type">Disease</infon>
        <location offset="100" length="29"/>
        <text>severe von Willebrand disease</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>131</offset>
      <text>Severe von Willebrand disease is characterized by undetectable or trace quantities of von Willebrand factor in plasma and tissue stores. We have studied the genomic DNA of 10 affected individuals from six families with this disorder using probes from the 5 and 3 ends of the vWF cDNA and with a probe extending from the 5 end into the central region. Southern blots of restriction endonuclease digests and gene dosage analysis measurements carried out with quantitative slot blots of undigested genomic DNA separated these patients into three groups. The first group consisted of a family with complete homozygous deletions of the vWF gene in the four probands. Gene dosage analysis was consistent with heterozygous deletions in both of the asymptomatic parents and four asymptomatic siblings of this kindred (P less than 0. 01). The second group was comprised of a family in which there was a complete heterozygous deletion of the vWF gene in the proband and one asymptomatic parent, suggesting that a different type of genetic abnormality was inherited from the other parent. Thus, the patient appeared to be doubly heterozygous for interacting genetic abnormalities affecting vWF expression. In the third group, no gene deletions could be detected. Alloantibodies developed only in the kindred with homozygous deletions. These techniques should prove useful in identifying carriers of severe von Willebrand disease and also in defining patients predictably at risk of developing alloantibodies to vWF. </text>
      <annotation id="2">
        <infon key="identifier">MESH:D056729</infon>
        <infon key="type">Disease</infon>
        <location offset="131" length="29"/>
        <text>Severe von Willebrand disease</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D014842</infon>
        <infon key="type">Disease</infon>
        <location offset="217" length="14"/>
        <text>von Willebrand</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D030342</infon>
        <infon key="type">Disease</infon>
        <location offset="1152" length="19"/>
        <text>genetic abnormality</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D030342</infon>
        <infon key="type">Disease</infon>
        <location offset="1278" length="21"/>
        <text>genetic abnormalities</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D056729</infon>
        <infon key="type">Disease</infon>
        <location offset="1519" length="29"/>
        <text>severe von Willebrand disease</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>409732</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Hereditary C7 deficiency. Diagnosis and HLA studies in a French-Canadian family.</text>
      <annotation id="0">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="24"/>
        <text>Hereditary C7 deficiency</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>81</offset>
      <text>The serum of a 44-yr-old woman of French-Canadian descent having a B-27 positive ankylosing spondylitis was deficient in the seventh component of complement (C7) as determined by hemolytic and immunochemical methods. No inhibitor against C7 was detected, and the levels of all other complement components were normal. No deficiency in the opsonic activity of the serum was found, and the results of basic coagulation studies of the plasma were normal. On investigation of the patients family, two sisters were found to have the same deficiency but were otherwise in good health. The seven other siblings were heterozygous for C7 deficiency, while the paternal aunt had a normal C7 level. In the third generation, six children of the three homozygous sisters and five children of heterozygotes were available for testing. Studies of the HLA antigens in all the 22 subjects and in three spouses indicated no close linkage between the CM deficienty and the HLA system. In addition, the simultaneous occurrence of two hereditary complement deficiencies (C2 and C7) was discovered in one family of this remarkable kindred.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D013167</infon>
        <infon key="type">Disease</infon>
        <location offset="162" length="22"/>
        <text>ankylosing spondylitis</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="189" length="48"/>
        <text>deficient in the seventh component of complement</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="707" length="13"/>
        <text>C7 deficiency</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="1013" length="13"/>
        <text>CM deficienty</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:C566443|OMIM:217000</infon>
        <infon key="type">Disease</infon>
        <location offset="1106" length="35"/>
        <text>complement deficiencies (C2 and C7)</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>7550230</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Three novel aniridia mutations in the human PAX6 gene.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="12" length="8"/>
        <text>aniridia</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>55</offset>
      <text>Aniridia (iris hypoplasia) is an autosomal dominant congenital disorder of the eye. Mutations in the human aniridia (PAX6) gene have now been identified in many patients from various ethnic groups. In the study reported here we describe PAX6 mutations in one sporadic and five familial cases with aniridia. Of the four different mutations identified, one was identical to a previously reported mutation (C-- &gt; T transition at codon 240), and three were novel  two in the glycine-rich region and one in the proline/serine/threonine-rich (PST) region. One PAX6 mutation found in the PST region was associated with cataracts in an aniridia family. Another splice mutation in the PST domain occurred in an aniridia patient with anosmia (inability to smell). The six new aniridia cases reported here have mutations predicted to generate incomplete PAX6 proteins. These results support the theory that human aniridia is caused by haploinsufficiency of PAX6.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="55" length="8"/>
        <text>Aniridia</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D007499</infon>
        <infon key="type">Disease</infon>
        <location offset="65" length="15"/>
        <text>iris hypoplasia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D005124</infon>
        <infon key="type">Disease</infon>
        <location offset="88" length="49"/>
        <text>autosomal dominant congenital disorder of the eye</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="162" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="352" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D002386</infon>
        <infon key="type">Disease</infon>
        <location offset="667" length="9"/>
        <text>cataracts</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="683" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="757" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D000857</infon>
        <infon key="type">Disease</infon>
        <location offset="779" length="7"/>
        <text>anosmia</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="821" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D015783</infon>
        <infon key="type">Disease</infon>
        <location offset="957" length="8"/>
        <text>aniridia</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:C536372</infon>
        <infon key="type">Disease</infon>
        <location offset="979" length="26"/>
        <text>haploinsufficiency of PAX6</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>7630639</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D018232</infon>
        <infon key="type">Disease</infon>
        <location offset="4" length="25"/>
        <text>alveolar rhabdomyosarcoma</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>87</offset>
      <text>Chimeric transcription factors, created by gene fusions as the result of chromosomal translocations, have been implicated in the pathogenesis of several pathologically disparate solid tumors. The PAX3/FKHR fusion gene, formed by a t (2; 13) (q35; q14) in alveolar rhabdomyosarcoma, encodes a hybrid protein that contains both PAX3 DNA binding domains, the paired box and homeodomain, linked to the bisected DNA binding domain of FKHR, a member of the forkhead family of transcription factors. Here we report that PAX3 and PAX3/FKHR display similar, but not identical transactivation activities when tested with model Pax recognition sequences. No functional role could be ascribed solely to the residual FKHR binding domain present in the fusion protein, but FKHR was found to contribute a strong carboxyl terminal activation domain replacing the one located in the unrearranged PAX3 gene. We show that the native PAX3/FKHR protein present in tumor cells with this translocation has transcriptional characteristics similar to the in vitro expressed protein. The ability of the PAX3/FKHR hybrid protein to bind DNA in a sequence specific manner and to transactivate the expression of artificial reporter genes suggests that its aberrant expression could subvert the transcriptional programs that normally control the growth, differentiation, and survival of primitive myogenic precursors in vivo.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="265" length="12"/>
        <text>solid tumors</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D018232</infon>
        <infon key="type">Disease</infon>
        <location offset="342" length="25"/>
        <text>alveolar rhabdomyosarcoma</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="1030" length="5"/>
        <text>tumor</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>7663517</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Rapid detection of BRCA1 mutations by the protein truncation test.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>67</offset>
      <text>More than 75% of the reported mutations in the hereditary breast and ovarian cancer gene, BRCA1, result in truncated proteins. We have used the protein truncation test (PTT) to screen for mutations in exon 11, which encodes 61% of BRCA1. In 45 patients from breast and/or ovarian cancer families we found six novel mutations  two single nucleotide insertions, three small deletions (1-5 bp) and a nonsense mutation identified two unrelated families. Furthermore, we were able to amplify the remaining coding region by RT-PCR using lymphocyte RNA. Combined with PTT, we detected aberrantly spliced products affecting exons 5 and 6 in one of two BRCA1-linked families examined. The protein truncation test promises to become a valuable technique in detecting BRCA1 mutations.. </text>
      <annotation id="0">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="114" length="36"/>
        <text>hereditary breast and ovarian cancer</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D001943|D010051</infon>
        <infon key="type">Disease</infon>
        <location offset="325" length="28"/>
        <text>breast and/or ovarian cancer</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>8401501</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="23" length="30"/>
        <text>breast-ovarian cancer syndrome</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>145</offset>
      <text>A susceptibility gene for hereditary breast-ovarian cancer, BRCA1, has been assigned by linkage analysis to chromosome 17q21. Candidate genes in this region include EDH17B2, which encodes estradiol 17 beta-hydroxysteroid dehydrogenase II (17 beta-HSD II), and RARA, the gene for retinoic acid receptor alpha. We have typed 22 breast and breast-ovarian cancer families with eight polymorphisms from the chromosome 17q12-21 region, including two in the EDH17B2 gene. Genetic recombination with the breast cancer trait excludes RARA from further consideration as a candidate gene for BRCA1. Both BRCA1 and EDH17B2 map to a 6 cM interval (between THRA1 and D17S579) and no recombination was observed between the two genes. However, direct sequencing of overlapping PCR products containing the entire EDH17B2 gene in four unrelated affected women did not uncover any sequence variation, other than previously described polymorphisms. Mutations in the EDH17B2 gene, therefore do not appear to be responsible for the hereditary breast-ovarian cancer syndrome. Single meiotic crossovers in affected women suggest that BRCA1 is flanked by the loci RARA and D17S78.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="171" length="32"/>
        <text>hereditary breast-ovarian cancer</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D001943|D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="471" length="32"/>
        <text>breast and breast-ovarian cancer</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="641" length="13"/>
        <text>breast cancer</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D061325</infon>
        <infon key="type">Disease</infon>
        <location offset="1155" length="41"/>
        <text>hereditary breast-ovarian cancer syndrome</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>9019400</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="11" length="5"/>
        <text>tumor</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="98" length="13"/>
        <text>breast cancer</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>113</offset>
      <text>Recent work has identified a mouse gene (tsg101) whose inactivation in fibroblasts results in cellular transformation and the ability to produce metastatic tumors in nude mice. Here, we report that the human homolog, TSG101, which we isolated and mapped to chromosome 11, bands 15. 1-15 1-15. 2, a region proposed to contain tumor suppressor gene (s), is mutated at high frequency in human breast cancer. In 7 of 15 uncultured primary human breast carcinomas, intragenic deletions were shown in TSG101 genomic DNA and transcripts by gel and sequence analysis, and mutations affecting two TSG101 alleles were identified in four of these cancers. No TSG101 defects were found in matched normal breast tissue from the breast cancer patients. These findings strongly implicate TSG101 mutations in human breast cancer </text>
      <annotation id="2">
        <infon key="identifier">MESH:D009362</infon>
        <infon key="type">Disease</infon>
        <location offset="258" length="17"/>
        <text>metastatic tumors</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="438" length="5"/>
        <text>tumor</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="503" length="13"/>
        <text>breast cancer</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="554" length="17"/>
        <text>breast carcinomas</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="749" length="7"/>
        <text>cancers</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="828" length="13"/>
        <text>breast cancer</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D001943</infon>
        <infon key="type">Disease</infon>
        <location offset="912" length="13"/>
        <text>breast cancer</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>9218625</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Molecular bases of C7 deficiency: three different defects.</text>
      <annotation id="0">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="19" length="13"/>
        <text>C7 deficiency</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>59</offset>
      <text>The molecular basis of C7 deficiency has been investigated in two Irish families and a number of Israeli families of Moroccan Sephardic Jewish origin. Exon PCR and sequencing revealed a heterozygous point mutation at the 3 splice acceptor site of intron 1 in one Irish family. In the other Irish family, exons 7 and 8 failed to amplify and they were shown to be deleted. Marker haplotype studies of the C6 and C7 gene region and Southern blots show that the Irish family with the splice defect also segregate for the deletion, which is not easily detected in heterozygotes. The Israeli C7-deficient cases all share a C7 haplotype and are homozygous for a mis-sense mutation in exon 9. However, one individual is heterozygous for markers at adjacent C6 loci, showing that there has been an intergenic recombination and suggesting that the deficiency mutation is of appreciable antiquity.. </text>
      <annotation id="1">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="82" length="13"/>
        <text>C7 deficiency</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:C566443</infon>
        <infon key="type">Disease</infon>
        <location offset="645" length="12"/>
        <text>C7-deficient</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>20520283</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D012559</infon>
        <infon key="type">Disease</infon>
        <location offset="119" length="13"/>
        <text>schizophrenia</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>134</offset>
      <text>Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity). With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P &lt; 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P &lt; 0.05). On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM. Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively. Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively. Across all groups, no more than 5% of patients had clinically significant weight change. Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D012559</infon>
        <infon key="type">Disease</infon>
        <location offset="226" length="13"/>
        <text>schizophrenia</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D001714</infon>
        <infon key="type">Disease</infon>
        <location offset="246" length="5"/>
        <text>manic</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D001714</infon>
        <infon key="type">Disease</infon>
        <location offset="286" length="18"/>
        <text>bipolar I disorder</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D011618</infon>
        <infon key="type">Disease</infon>
        <location offset="321" length="9"/>
        <text>psychotic</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D012559</infon>
        <infon key="type">Disease</infon>
        <location offset="397" length="13"/>
        <text>schizophrenia</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D001480</infon>
        <infon key="type">Disease</infon>
        <location offset="1500" length="23"/>
        <text>Extrapyramidal symptoms</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D001480</infon>
        <infon key="type">Disease</infon>
        <location offset="1884" length="23"/>
        <text>extrapyramidal symptoms</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10365197</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="16" length="13"/>
        <text>mood disorder</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D001523</infon>
        <infon key="type">Disease</infon>
        <location offset="52" length="11"/>
        <text>psychiatric</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>116</offset>
      <text>This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms. The prevalence rate for CIMD was 12% at baseline. Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders. Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder. These findings suggest some validity for the new DSM-IV diagnosis of CIMD, but also suggest that it requires further specification and replication.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="232" length="14"/>
        <text>mood disorders</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="303" length="13"/>
        <text>mood disorder</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D019970</infon>
        <infon key="type">Disease</infon>
        <location offset="318" length="4"/>
        <text>CIMD</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="331" length="14"/>
        <text>mood disorders</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="353" length="13"/>
        <text>mood disorder</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D001523</infon>
        <infon key="type">Disease</infon>
        <location offset="396" length="11"/>
        <text>psychiatric</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D019970</infon>
        <infon key="type">Disease</infon>
        <location offset="442" length="4"/>
        <text>CIMD</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D019970</infon>
        <infon key="type">Disease</infon>
        <location offset="508" length="4"/>
        <text>CIMD</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D003866</infon>
        <infon key="type">Disease</infon>
        <location offset="561" length="20"/>
        <text>depressive disorders</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D019970</infon>
        <infon key="type">Disease</infon>
        <location offset="597" length="4"/>
        <text>CIMD</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D019964</infon>
        <infon key="type">Disease</infon>
        <location offset="675" length="13"/>
        <text>mood disorder</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D019970</infon>
        <infon key="type">Disease</infon>
        <location offset="759" length="4"/>
        <text>CIMD</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10523326</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Nitric oxide synthase expression in the course of lead-induced hypertension.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="63" length="12"/>
        <text>hypertension</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>77</offset>
      <text>We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension. This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression. Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks. Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured. The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression. Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression. Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group. The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations. In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression. This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="280" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="382" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="1160" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="1582" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="1878" length="12"/>
        <text>hypertension</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>10579464</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>98</offset>
      <text>NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively. NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor. NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice. NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task. These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006948</infon>
        <infon key="type">Disease</infon>
        <location offset="683" length="13"/>
        <text>hyperactivity</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D002375</infon>
        <infon key="type">Disease</infon>
        <location offset="945" length="9"/>
        <text>catalepsy</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>11027905</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="44" length="6"/>
        <text>cancer</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>151</offset>
      <text>Pain not responsive to morphine is often problematic. Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of diazepam 1 mg intravenously. Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg. A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine. Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain. However, the occurrence of central adverse effects should be taken into account, especially when using higher doses. This observation should be tested in studies of prolonged ketamine administration.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="151" length="4"/>
        <text>Pain</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="372" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D009437</infon>
        <infon key="type">Disease</infon>
        <location offset="396" length="16"/>
        <text>neuropathic pain</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D009369</infon>
        <infon key="type">Disease</infon>
        <location offset="503" length="6"/>
        <text>cancer</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="525" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="618" length="4"/>
        <text>Pain</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D009325</infon>
        <infon key="type">Disease</infon>
        <location offset="663" length="6"/>
        <text>nausea</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D014839</infon>
        <infon key="type">Disease</infon>
        <location offset="674" length="8"/>
        <text>vomiting</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D003221</infon>
        <infon key="type">Disease</infon>
        <location offset="696" length="9"/>
        <text>confusion</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D014987</infon>
        <infon key="type">Disease</infon>
        <location offset="711" length="9"/>
        <text>dry mouth</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1052" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D006212</infon>
        <infon key="type">Disease</infon>
        <location offset="1178" length="14"/>
        <text>Hallucinations</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1675" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D009437</infon>
        <infon key="type">Disease</infon>
        <location offset="1699" length="16"/>
        <text>neuropathic pain</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>11079278</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D017202</infon>
        <infon key="type">Disease</infon>
        <location offset="95" length="19"/>
        <text>myocardial ischemia</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>116</offset>
      <text>STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Community hospital. PATIENTS: Twenty-two patients with known reversible perfusion defects. INTERVENTION: Patients underwent dobutamine stress tests per standard protocol. Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg. Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg. MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control. Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control. Summed stress and summed difference scores were not significantly reduced, although they were 18% and 30% lower, respectively, than control. No significant differences were found in any parameter between metoprolol and metoprolol-glucagon. CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia. Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D017202</infon>
        <infon key="type">Disease</infon>
        <location offset="1493" length="19"/>
        <text>myocardial ischemia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>11912119</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Force overflow and levodopa-induced dyskinesias in Parkinson's disease.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="36" length="11"/>
        <text>dyskinesias</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="51" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>72</offset>
      <text>We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID). We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls. The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa. A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only. In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P &lt; 0.05). An overshooting of peak grip force by 51% (P &lt; 0.05) and of static grip force by 45% (P &lt; 0.01) was observed in the ON- compared with the OFF-drug condition. In contrast, no excessive force was found in Parkinson's disease - LID. Peak grip force in ON-state was 140% (P &lt; 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P &lt; 0.01) between groups. Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P &lt; 0.01). No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication. Force excess was only observed in patients with LID and motor fluctuations. A close relationship was seen between the overshooting of forces and dyskinesias in the ON-drug condition. We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="118" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="236" length="11"/>
        <text>dyskinesias</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="249" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="280" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="315" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="337" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="379" length="11"/>
        <text>dyskinesias</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="392" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="414" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="493" length="19"/>
        <text>Parkinson's Disease</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="529" length="10"/>
        <text>dyskinesia</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="673" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="695" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="708" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="730" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="1060" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1082" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="19">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="1145" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="20">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1167" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="21">
        <infon key="identifier">MESH:D010300</infon>
        <infon key="type">Disease</infon>
        <location offset="1179" length="19"/>
        <text>Parkinson's disease</text>
      </annotation>
      <annotation id="22">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1201" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="23">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1301" length="11"/>
        <text>dyskinesias</text>
      </annotation>
      <annotation id="24">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1573" length="3"/>
        <text>LID</text>
      </annotation>
      <annotation id="25">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1670" length="11"/>
        <text>dyskinesias</text>
      </annotation>
      <annotation id="26">
        <infon key="identifier">MESH:D004409</infon>
        <infon key="type">Disease</infon>
        <location offset="1731" length="3"/>
        <text>LID</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>12042105</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Topiramate-induced nephrolithiasis.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D053040</infon>
        <infon key="type">Disease</infon>
        <location offset="19" length="15"/>
        <text>nephrolithiasis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>36</offset>
      <text>Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures. Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase. In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis. We report the first two cases of topiramate-induced nephrolithiasis in the urologic literature.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D004827</infon>
        <infon key="type">Disease</infon>
        <location offset="172" length="19"/>
        <text>refractory seizures</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="251" length="18"/>
        <text>metabolic acidosis</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D053040</infon>
        <infon key="type">Disease</infon>
        <location offset="512" length="15"/>
        <text>nephrolithiasis</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D053040</infon>
        <infon key="type">Disease</infon>
        <location offset="581" length="15"/>
        <text>nephrolithiasis</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>12716030</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006470</infon>
        <infon key="type">Disease</infon>
        <location offset="10" length="8"/>
        <text>bleeding</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D006406</infon>
        <infon key="type">Disease</infon>
        <location offset="23" length="8"/>
        <text>hematoma</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="64" length="24"/>
        <text>intracerebral hemorrhage</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>100</offset>
      <text>The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully. We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration. In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume. The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration. In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold. Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.</text>
      <annotation id="3">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="123" length="24"/>
        <text>intracerebral hemorrhage</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="149" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="174" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="298" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="325" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="347" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D006470</infon>
        <infon key="type">Disease</infon>
        <location offset="444" length="8"/>
        <text>bleeding</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D006406</infon>
        <infon key="type">Disease</infon>
        <location offset="575" length="8"/>
        <text>hematoma</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D006406</infon>
        <infon key="type">Disease</infon>
        <location offset="614" length="8"/>
        <text>hematoma</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D006406</infon>
        <infon key="type">Disease</infon>
        <location offset="670" length="8"/>
        <text>hematoma</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="736" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="758" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D006406</infon>
        <infon key="type">Disease</infon>
        <location offset="823" length="8"/>
        <text>hematoma</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="874" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D006470</infon>
        <infon key="type">Disease</infon>
        <location offset="894" length="8"/>
        <text>bleeding</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="977" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="19">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="1022" length="3"/>
        <text>ICH</text>
      </annotation>
      <annotation id="20">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="1117" length="3"/>
        <text>ICH</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>14659530</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="11" length="8"/>
        <text>migraine</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>165</offset>
      <text>The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura) and eight controls participated in the study. Sublingual nitroglycerin (0.5 mg) was administered. Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects). In those subjects who had no migraine attack (11 subjects) a similar time schedule was used. Plasma CGRP concentration increased significantly (P&lt;0.01) during the migraine attack and returned to baseline after the cessation of the migraine. In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P&lt;0.001). However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack. Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack. Platelet serotonin content decreased significantly (P&lt;0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack. In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine. In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="368" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="401" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D020326</infon>
        <infon key="type">Disease</infon>
        <location offset="459" length="26"/>
        <text>migraineurs (without aura)</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="743" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="825" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="959" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1027" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1118" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="1127" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="1227" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1264" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1406" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1523" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1594" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1711" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="1720" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1777" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="1850" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="19">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="1887" length="8"/>
        <text>headache</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>15974569</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="106" length="4"/>
        <text>pain</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>112</offset>
      <text>Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors. Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="339" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D006930</infon>
        <infon key="type">Disease</infon>
        <location offset="407" length="20"/>
        <text>thermal hyperalgesia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D006930</infon>
        <infon key="type">Disease</infon>
        <location offset="451" length="23"/>
        <text>mechanical hyperalgesia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>16005948</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D062787</infon>
        <infon key="type">Disease</infon>
        <location offset="82" length="16"/>
        <text>cocaine overdose</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>100</offset>
      <text>The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive. Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects. The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose. Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg. GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment. Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%. Importantly, GNC92H2 prevented death even post-cocaine injection. The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D062787</infon>
        <infon key="type">Disease</infon>
        <location offset="179" length="16"/>
        <text>cocaine overdose</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D062787</infon>
        <infon key="type">Disease</infon>
        <location offset="456" length="16"/>
        <text>cocaine overdose</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="780" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="897" length="8"/>
        <text>seizures</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D003643</infon>
        <infon key="type">Disease</infon>
        <location offset="920" length="5"/>
        <text>death</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D003643</infon>
        <infon key="type">Disease</infon>
        <location offset="965" length="5"/>
        <text>death</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D062787</infon>
        <infon key="type">Disease</infon>
        <location offset="1085" length="16"/>
        <text>cocaine overdose</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>16720068</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="9" length="30"/>
        <text>neuroleptic malignant syndrome</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>105</offset>
      <text>A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion. Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D003866</infon>
        <infon key="type">Disease</infon>
        <location offset="128" length="19"/>
        <text>depressive symptoms</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D001523</infon>
        <infon key="type">Disease</infon>
        <location offset="166" length="11"/>
        <text>psychiatric</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D007319</infon>
        <infon key="type">Disease</infon>
        <location offset="194" length="8"/>
        <text>insomnia</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D001068</infon>
        <infon key="type">Disease</infon>
        <location offset="204" length="16"/>
        <text>loss of appetite</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D011595</infon>
        <infon key="type">Disease</infon>
        <location offset="238" length="9"/>
        <text>agitation</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D011596</infon>
        <infon key="type">Disease</infon>
        <location offset="425" length="23"/>
        <text>psychomotor retardation</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="477" length="15"/>
        <text>muscle rigidity</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D014202</infon>
        <infon key="type">Disease</infon>
        <location offset="498" length="7"/>
        <text>tremors</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D005334</infon>
        <infon key="type">Disease</infon>
        <location offset="525" length="5"/>
        <text>fever</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D001480</infon>
        <infon key="type">Disease</infon>
        <location offset="625" length="23"/>
        <text>extrapyramidal symptoms</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D005334</infon>
        <infon key="type">Disease</infon>
        <location offset="919" length="5"/>
        <text>fever</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="1040" length="30"/>
        <text>neuroleptic malignant syndrome</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="1072" length="3"/>
        <text>NMS</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="1102" length="3"/>
        <text>NMS</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="1324" length="3"/>
        <text>NMS</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D009459</infon>
        <infon key="type">Disease</infon>
        <location offset="1518" length="3"/>
        <text>NMS</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D003866</infon>
        <infon key="type">Disease</infon>
        <location offset="1549" length="10"/>
        <text>depressive</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D003681</infon>
        <infon key="type">Disease</infon>
        <location offset="1598" length="11"/>
        <text>dehydration</text>
      </annotation>
      <annotation id="19">
        <infon key="identifier">MESH:D011595</infon>
        <infon key="type">Disease</infon>
        <location offset="1611" length="9"/>
        <text>agitation</text>
      </annotation>
      <annotation id="20">
        <infon key="identifier">MESH:D044342</infon>
        <infon key="type">Disease</infon>
        <location offset="1622" length="12"/>
        <text>malnutrition</text>
      </annotation>
      <annotation id="21">
        <infon key="identifier">MESH:D003866</infon>
        <infon key="type">Disease</infon>
        <location offset="1750" length="10"/>
        <text>depression</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>17242861</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Use of chromosome substitution strains to identify seizure susceptibility loci in mice.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="51" length="7"/>
        <text>seizure</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>88</offset>
      <text>Seizure susceptibility varies among inbred mouse strains. Chromosome substitution strains (CSS), in which a single chromosome from one inbred strain (donor) has been transferred onto a second strain (host) by repeated backcrossing, may be used to identify quantitative trait loci (QTLs) that contribute to seizure susceptibility. QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes. We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures. Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures. Highest stage reached and latency to each stage were recorded for all mice. B6 mice were resistant to seizures and slower to reach stages compared to A/J mice. The CSS for Chromosomes 10 and 18 progressed to the most severe stages, diverging dramatically from the B6 phenotype. Latencies to stages were also significantly shorter for CSS10 and CSS18 mice. CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18. This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="88" length="7"/>
        <text>Seizure</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="394" length="7"/>
        <text>seizure</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="465" length="8"/>
        <text>seizures</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D004833</infon>
        <infon key="type">Disease</infon>
        <location offset="486" length="22"/>
        <text>temporal lobe epilepsy</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="584" length="7"/>
        <text>seizure</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="750" length="8"/>
        <text>seizures</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="878" length="8"/>
        <text>seizures</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="990" length="8"/>
        <text>seizures</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D012640</infon>
        <infon key="type">Disease</infon>
        <location offset="1265" length="7"/>
        <text>seizure</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D004833</infon>
        <infon key="type">Disease</infon>
        <location offset="1431" length="22"/>
        <text>temporal lobe epilepsy</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>18186898</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?</text>
      <annotation id="0">
        <infon key="identifier">MESH:D005198</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="22"/>
        <text>Renal Fanconi syndrome</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D009135</infon>
        <infon key="type">Disease</infon>
        <location offset="27" length="8"/>
        <text>myopathy</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:C540770</infon>
        <infon key="type">Disease</infon>
        <location offset="78" length="23"/>
        <text>mitochondrial cytopathy</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>103</offset>
      <text>Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. Tacrolimus, MMF, and steroids were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA. We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.</text>
      <annotation id="3">
        <infon key="identifier">MESH:D006527</infon>
        <infon key="type">Disease</infon>
        <location offset="444" length="16"/>
        <text>Wilson's disease</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D006509</infon>
        <infon key="type">Disease</infon>
        <location offset="565" length="21"/>
        <text>hepatitis B infection</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D005198</infon>
        <infon key="type">Disease</infon>
        <location offset="654" length="22"/>
        <text>renal Fanconi syndrome</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="689" length="18"/>
        <text>metabolic acidosis</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D017674</infon>
        <infon key="type">Disease</infon>
        <location offset="709" length="16"/>
        <text>hypophosphatemia</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D006029</infon>
        <infon key="type">Disease</infon>
        <location offset="727" length="10"/>
        <text>glycosuria</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D000608</infon>
        <infon key="type">Disease</infon>
        <location offset="743" length="13"/>
        <text>aminoaciduria</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="838" length="8"/>
        <text>acidosis</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="878" length="8"/>
        <text>acidosis</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D018908</infon>
        <infon key="type">Disease</infon>
        <location offset="934" length="15"/>
        <text>muscle weakness</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D005198</infon>
        <infon key="type">Disease</infon>
        <location offset="986" length="16"/>
        <text>Fanconi syndrome</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D009135</infon>
        <infon key="type">Disease</infon>
        <location offset="1015" length="8"/>
        <text>myopathy</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D028361</infon>
        <infon key="type">Disease</infon>
        <location offset="1061" length="23"/>
        <text>mitochondrial disorders</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D005198</infon>
        <infon key="type">Disease</infon>
        <location offset="1149" length="19"/>
        <text>tubular dysfunction</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D009135</infon>
        <infon key="type">Disease</infon>
        <location offset="1173" length="8"/>
        <text>myopathy</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D028361</infon>
        <infon key="type">Disease</infon>
        <location offset="1205" length="25"/>
        <text>mitochondrial dysfunction</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>18201582</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="260" length="12"/>
        <text>hypertension</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>274</offset>
      <text>OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension. METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension. Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position. Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP &lt;130/&lt;80 mm Hg) at end of study. Tolerability was assessed by treatment-emergent adverse events, identified using physical examination, laboratory analysis, and electrocardiography. RESULTS: A total of 210 patients were enrolled in the study; 203 patients (143 men, 60 women) completed the study while 7 were lost to follow-up (4 patients in the T+A group and 3 in the A group) and considered with-drawn. At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P &lt; 0.05). Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P &lt; 0.05). The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]). Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance. The incidences of headache, dizziness, and diarrhea were similar between the 2 groups. CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="521" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="718" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D004487</infon>
        <infon key="type">Disease</infon>
        <location offset="1939" length="5"/>
        <text>edema</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D003371</infon>
        <infon key="type">Disease</infon>
        <location offset="2049" length="5"/>
        <text>cough</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="2228" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D004244</infon>
        <infon key="type">Disease</infon>
        <location offset="2238" length="9"/>
        <text>dizziness</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D003967</infon>
        <infon key="type">Disease</infon>
        <location offset="2253" length="8"/>
        <text>diarrhea</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="2352" length="12"/>
        <text>hypertension</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>18221780</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="111" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="146" length="10"/>
        <text>acute pain</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>158</offset>
      <text>In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females. The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus. To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured. For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures. In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner. Across the doses and pretreatment times examined, enhancement was not observed in females. Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males. These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="161" length="10"/>
        <text>acute pain</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="390" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="435" length="10"/>
        <text>acute pain</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D006930</infon>
        <infon key="type">Disease</infon>
        <location offset="595" length="12"/>
        <text>hyperalgesia</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="854" length="10"/>
        <text>acute pain</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="1296" length="10"/>
        <text>acute pain</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1487" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D059787</infon>
        <infon key="type">Disease</infon>
        <location offset="1547" length="10"/>
        <text>acute pain</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>18405372</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="14"/>
        <text>Hepatotoxicity</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D001168</infon>
        <infon key="type">Disease</infon>
        <location offset="61" length="9"/>
        <text>arthritis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>139</offset>
      <text>BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases. We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients. METHODS: Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years. Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified. Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument. The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions. RESULTS: Ten cases were identified: eight occurred during surveillance. Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant. All but one event occurred within 6 weeks of treatment. Seven patients had a skin rash, three eosinophilia and one interstitial nephritis. Five patients were of Black British of African or Caribbean descent. Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six. Drug-related hepatotoxicity was judged probable or highly probable in 8 patients. The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients. CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D017093</infon>
        <infon key="type">Disease</infon>
        <location offset="473" length="13"/>
        <text>liver failure</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="649" length="14"/>
        <text>hepatotoxicity</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="893" length="14"/>
        <text>hepatotoxicity</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D017093</infon>
        <infon key="type">Disease</infon>
        <location offset="1102" length="15"/>
        <text>hepatic failure</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D005076</infon>
        <infon key="type">Disease</infon>
        <location offset="1232" length="9"/>
        <text>skin rash</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D004802</infon>
        <infon key="type">Disease</infon>
        <location offset="1249" length="12"/>
        <text>eosinophilia</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D009395</infon>
        <infon key="type">Disease</infon>
        <location offset="1270" length="22"/>
        <text>interstitial nephritis</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="1464" length="14"/>
        <text>hepatotoxicity</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="1565" length="14"/>
        <text>hepatotoxicity</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="1662" length="14"/>
        <text>hepatotoxicity</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>18821488</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).</text>
      <annotation id="0">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="8"/>
        <text>Toxicity</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>165</offset>
      <text>INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity. Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment. Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment. METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg. Health status and MHb levels were monitored following exposure. RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean &lt; 2.0%) in the rhesus monkey. Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose. Myoglobinuria was also observed following the 7.0 mg/kg dose. Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity, with greater severity in the orally-treated animal. CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity. It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="258" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D011041</infon>
        <infon key="type">Disease</infon>
        <location offset="332" length="9"/>
        <text>poisoning</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D008708</infon>
        <infon key="type">Disease</infon>
        <location offset="976" length="17"/>
        <text>methemoglobinemia</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D006456</infon>
        <infon key="type">Disease</infon>
        <location offset="1133" length="14"/>
        <text>hemoglobinuria</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D009212</infon>
        <infon key="type">Disease</infon>
        <location offset="1306" length="13"/>
        <text>Myoglobinuria</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D056486|D007674</infon>
        <infon key="type">Disease</infon>
        <location offset="1428" length="25"/>
        <text>liver and kidney toxicity</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="1579" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D011041</infon>
        <infon key="type">Disease</infon>
        <location offset="1666" length="9"/>
        <text>poisoning</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="1793" length="8"/>
        <text>toxicity</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>1899352</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>81</offset>
      <text>Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna. The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna. Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1). The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion. Because few patients received multiple courses over time, the cumulative effects are indeterminate in the present trial. The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria. The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle. Clinical activity was demonstrated in a single patient, but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006417</infon>
        <infon key="type">Disease</infon>
        <location offset="507" length="9"/>
        <text>hematuria</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D006417</infon>
        <infon key="type">Disease</infon>
        <location offset="586" length="9"/>
        <text>hematuria</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="652" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D003221</infon>
        <infon key="type">Disease</infon>
        <location offset="662" length="9"/>
        <text>confusion</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D009325</infon>
        <infon key="type">Disease</infon>
        <location offset="677" length="6"/>
        <text>nausea</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D007970</infon>
        <infon key="type">Disease</infon>
        <location offset="701" length="10"/>
        <text>leukopenia</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D006417</infon>
        <infon key="type">Disease</infon>
        <location offset="1046" length="9"/>
        <text>hematuria</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D006417</infon>
        <infon key="type">Disease</infon>
        <location offset="1192" length="9"/>
        <text>hematuria</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>19581773</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009157</infon>
        <infon key="type">Disease</infon>
        <location offset="15" length="17"/>
        <text>ocular myasthenia</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D019698</infon>
        <infon key="type">Disease</infon>
        <location offset="89" length="19"/>
        <text>chronic hepatitis C</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>110</offset>
      <text>A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal. The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin. The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D004172</infon>
        <infon key="type">Disease</infon>
        <location offset="148" length="8"/>
        <text>diplopia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D019698</infon>
        <infon key="type">Disease</infon>
        <location offset="246" length="19"/>
        <text>chronic hepatitis C</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D019698</infon>
        <infon key="type">Disease</infon>
        <location offset="267" length="3"/>
        <text>CHC</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D001763</infon>
        <infon key="type">Disease</infon>
        <location offset="308" length="29"/>
        <text>ptosis on the right upper lid</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D015835</infon>
        <infon key="type">Disease</infon>
        <location offset="342" length="29"/>
        <text>restricted right eye movement</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D009157</infon>
        <infon key="type">Disease</infon>
        <location offset="788" length="17"/>
        <text>ocular myasthenia</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D019698</infon>
        <infon key="type">Disease</infon>
        <location offset="886" length="3"/>
        <text>CHC</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>19674115</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Recurrent dysosmia induced by pyrazinamide.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D000857</infon>
        <infon key="type">Disease</infon>
        <location offset="10" length="8"/>
        <text>dysosmia</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>44</offset>
      <text>Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders. In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs. We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge. The patient presented every day a sensation of smelling something burning 15 min after drug intake. Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge. The case was reported to the Tunisian Centre of Pharmacovigilance.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D056486</infon>
        <infon key="type">Disease</infon>
        <location offset="90" length="16"/>
        <text>hepatic toxicity</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D033461</infon>
        <infon key="type">Disease</infon>
        <location offset="108" length="13"/>
        <text>hyperuricemia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D000857</infon>
        <infon key="type">Disease</infon>
        <location offset="300" length="18"/>
        <text>olfactory disorder</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D000857</infon>
        <infon key="type">Disease</infon>
        <location offset="484" length="8"/>
        <text>Dysosmia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>20635749</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="7" length="24"/>
        <text>congestive heart failure</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D009230|D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="70" length="14"/>
        <text>myxedemic coma</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>101</offset>
      <text>This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF). To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy. Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D009230|D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="126" length="13"/>
        <text>myxedema coma</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D007037</infon>
        <infon key="type">Disease</infon>
        <location offset="172" length="14"/>
        <text>hypothyroidism</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="212" length="24"/>
        <text>congestive heart failure</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="238" length="3"/>
        <text>CHF</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D009230|D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="324" length="13"/>
        <text>myxedema coma</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D009230|D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="375" length="13"/>
        <text>Myxedema coma</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="597" length="3"/>
        <text>CHF</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D007037</infon>
        <infon key="type">Disease</infon>
        <location offset="663" length="14"/>
        <text>hypothyroidism</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="867" length="3"/>
        <text>CHF</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D009230|D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="917" length="13"/>
        <text>myxedema coma</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="1029" length="3"/>
        <text>CHF</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="1058" length="11"/>
        <text>hypotension</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D018908</infon>
        <infon key="type">Disease</infon>
        <location offset="1071" length="8"/>
        <text>weakness</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2334179</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>D-penicillamine in the treatment of localized scleroderma.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D012594</infon>
        <infon key="type">Disease</infon>
        <location offset="36" length="21"/>
        <text>localized scleroderma</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>59</offset>
      <text>Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children. There is no accepted or proven treatment for localized scleroderma. Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article. This drug was judged to have a favorable effect on the disease course in 7 (64%) of 11 patients. Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children. Joint stiffness and contractures also improved. The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months. D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency. These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D012594</infon>
        <infon key="type">Disease</infon>
        <location offset="59" length="21"/>
        <text>Localized scleroderma</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D012594</infon>
        <infon key="type">Disease</infon>
        <location offset="269" length="21"/>
        <text>localized scleroderma</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D012594</infon>
        <infon key="type">Disease</infon>
        <location offset="343" length="21"/>
        <text>localized scleroderma</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D003286</infon>
        <infon key="type">Disease</infon>
        <location offset="750" length="12"/>
        <text>contractures</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D009404</infon>
        <infon key="type">Disease</infon>
        <location offset="951" length="18"/>
        <text>nephrotic syndrome</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D011507</infon>
        <infon key="type">Disease</infon>
        <location offset="1005" length="11"/>
        <text>proteinuria</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D051437</infon>
        <infon key="type">Disease</infon>
        <location offset="1053" length="19"/>
        <text>renal insufficiency</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D012594</infon>
        <infon key="type">Disease</infon>
        <location offset="1150" length="21"/>
        <text>localized scleroderma</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2425813</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>112</offset>
      <text>Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone. In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle. It is suggested that the drug acted in a selective and tissue-specific manner to enhance ribosomal RNA synthesis in the liver and depress such synthesis in the muscle. This view supports the contention that the liver and muscle are independent sites of prednisolone action.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006529</infon>
        <infon key="type">Disease</infon>
        <location offset="112" length="17"/>
        <text>Liver enlargement</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D009133</infon>
        <infon key="type">Disease</infon>
        <location offset="134" length="14"/>
        <text>muscle wastage</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2673163</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Stroke associated with cocaine use.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="6"/>
        <text>Stroke</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>36</offset>
      <text>We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature. Among these 47 patients the mean (+/- SD) age was 32.5 +/- 12.1 years; 76% (34/45) were men. Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes. Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients. Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%). These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="98" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="239" length="6"/>
        <text>Stroke</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D002532</infon>
        <infon key="type">Disease</infon>
        <location offset="333" length="22"/>
        <text>Intracranial aneurysms</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D001165</infon>
        <infon key="type">Disease</infon>
        <location offset="359" length="27"/>
        <text>arteriovenous malformations</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D020293</infon>
        <infon key="type">Disease</infon>
        <location offset="461" length="19"/>
        <text>cerebral vasculitis</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D002544</infon>
        <infon key="type">Disease</infon>
        <location offset="510" length="19"/>
        <text>Cerebral infarction</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D002543</infon>
        <infon key="type">Disease</infon>
        <location offset="561" length="24"/>
        <text>intracerebral hemorrhage</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D013345</infon>
        <infon key="type">Disease</infon>
        <location offset="603" length="23"/>
        <text>subarachnoid hemorrhage</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="695" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="763" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="808" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="867" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D002532</infon>
        <infon key="type">Disease</infon>
        <location offset="922" length="22"/>
        <text>intracranial aneurysms</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D001165</infon>
        <infon key="type">Disease</infon>
        <location offset="949" length="27"/>
        <text>arteriovenous malformations</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D020521</infon>
        <infon key="type">Disease</infon>
        <location offset="1008" length="6"/>
        <text>stroke</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D020300</infon>
        <infon key="type">Disease</infon>
        <location offset="1033" length="23"/>
        <text>intracranial hemorrhage</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D002544</infon>
        <infon key="type">Disease</infon>
        <location offset="1073" length="19"/>
        <text>cerebral infarction</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2819587</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Magnetic resonance imaging of cerebral venous thrombosis secondary to "low-dose" birth control pills.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D020246</infon>
        <infon key="type">Disease</infon>
        <location offset="39" length="17"/>
        <text>venous thrombosis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>102</offset>
      <text>The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented. This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes. The only known risk factor was "low-dose" oral contraceptive pills. The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus. The diagnosis was confirmed by arterial angiography.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D020246</infon>
        <infon key="type">Disease</infon>
        <location offset="153" length="22"/>
        <text>deep venous thrombosis</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>2950248</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Dipyridamole-induced myocardial ischemia.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D017202</infon>
        <infon key="type">Disease</infon>
        <location offset="21" length="19"/>
        <text>myocardial ischemia</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>42</offset>
      <text>Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures. To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease. Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary "steal" phenomenon may be the mechanism of the dipyridamole-induced ischemia observed.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D000787</infon>
        <infon key="type">Disease</infon>
        <location offset="42" length="6"/>
        <text>Angina</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D017202</infon>
        <infon key="type">Disease</infon>
        <location offset="357" length="19"/>
        <text>myocardial ischemia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D003324</infon>
        <infon key="type">Disease</infon>
        <location offset="435" length="23"/>
        <text>coronary artery disease</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D007511</infon>
        <infon key="type">Disease</infon>
        <location offset="618" length="8"/>
        <text>ischemia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3015327</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009422</infon>
        <infon key="type">Disease</infon>
        <location offset="57" length="10"/>
        <text>neuropathy</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>80</offset>
      <text>The neuropathy caused by a single dose of isoniazid in rats was studied with a computer-assisted morphometric method. Scatter diagrams of the g ratio (quotient fibre diameter/axon diameter) define regenerating fibres as a distinct population, distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre. There was also evidence of a subtle direct toxic effect on the entire fibre population, causing axon shrinkage masked by readjustment of the myelin sheath.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D009422</infon>
        <infon key="type">Disease</infon>
        <location offset="84" length="10"/>
        <text>neuropathy</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3084782</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Toxicity due to remission inducing drugs in rheumatoid arthritis. Association with HLA-B35 and Cw4 antigens.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="8"/>
        <text>Toxicity</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D001172</infon>
        <infon key="type">Disease</infon>
        <location offset="44" length="20"/>
        <text>rheumatoid arthritis</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>109</offset>
      <text>Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens. A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35. Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D001172</infon>
        <infon key="type">Disease</infon>
        <location offset="135" length="20"/>
        <text>rheumatoid arthritis</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D001172</infon>
        <infon key="type">Disease</infon>
        <location offset="157" length="2"/>
        <text>RA</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="175" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D064420</infon>
        <infon key="type">Disease</infon>
        <location offset="237" length="8"/>
        <text>toxicity</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D009393</infon>
        <infon key="type">Disease</infon>
        <location offset="363" length="9"/>
        <text>nephritis</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D003872</infon>
        <infon key="type">Disease</infon>
        <location offset="377" length="10"/>
        <text>dermatitis</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D003872</infon>
        <infon key="type">Disease</infon>
        <location offset="481" length="10"/>
        <text>dermatitis</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D001172</infon>
        <infon key="type">Disease</infon>
        <location offset="607" length="2"/>
        <text>RA</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D009393</infon>
        <infon key="type">Disease</infon>
        <location offset="643" length="9"/>
        <text>nephritis</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3403780</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D003128</infon>
        <infon key="type">Disease</infon>
        <location offset="23" length="4"/>
        <text>coma</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="29" length="18"/>
        <text>metabolic acidosis</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D058186|D017093</infon>
        <infon key="type">Disease</infon>
        <location offset="49" length="25"/>
        <text>renal and hepatic failure</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>76</offset>
      <text>A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented. The diagnostic difficulty at presentation is highlighted. Continuous arteriovenous haemofiltration proved a valuable means of maintaining fluid and electrolyte balance. The patient recovered.</text>
      <annotation id="3">
        <infon key="identifier">MESH:D000138</infon>
        <infon key="type">Disease</infon>
        <location offset="86" length="18"/>
        <text>metabolic acidosis</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D058186|D017114</infon>
        <infon key="type">Disease</infon>
        <location offset="106" length="39"/>
        <text>acute renal failure and hepatic failure</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3676049</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="61" length="11"/>
        <text>hypotension</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D002532</infon>
        <infon key="type">Disease</infon>
        <location offset="110" length="18"/>
        <text>cerebral aneurysms</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>130</offset>
      <text>Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm. Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%. This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged. After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%. There was a significant increase in CBF, although CMRO2 was unchanged, compared with pre-hypotensive values. These changes might offer protection to brain tissue during periods of induced hypotension.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="229" length="11"/>
        <text>hypotension</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D002532</infon>
        <infon key="type">Disease</infon>
        <location offset="298" length="17"/>
        <text>cerebral aneurysm</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D013345</infon>
        <infon key="type">Disease</infon>
        <location offset="371" length="24"/>
        <text>subarachnoid haemorrhage</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="734" length="11"/>
        <text>hypotension</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D000783</infon>
        <infon key="type">Disease</infon>
        <location offset="1025" length="8"/>
        <text>aneurysm</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="1174" length="11"/>
        <text>hypotensive</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="1273" length="11"/>
        <text>hypotension</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>3780697</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Post-operative rigidity after fentanyl administration.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="15" length="8"/>
        <text>rigidity</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>55</offset>
      <text>A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl. This was successfully reversed by naloxone. The mechanisms possibly implicated in this accident are discussed.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="83" length="8"/>
        <text>rigidity</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D012131</infon>
        <infon key="type">Disease</infon>
        <location offset="103" length="19"/>
        <text>respiratory failure</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>6115999</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="78" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="161" length="12"/>
        <text>Hypertension</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>175</offset>
      <text>Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs. The trial is single-blind. 23 582 patient-years of observation have been completed so far, 10 684 on active drugs and 12 898 on placebos. The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos. Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide. In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.</text>
      <annotation id="2">
        <infon key="identifier">MESH:D006973</infon>
        <infon key="type">Disease</infon>
        <location offset="245" length="12"/>
        <text>hypertension</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D007172</infon>
        <infon key="type">Disease</infon>
        <location offset="590" length="9"/>
        <text>impotence</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D007172</infon>
        <infon key="type">Disease</infon>
        <location offset="605" length="9"/>
        <text>impotence</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D018149</infon>
        <infon key="type">Disease</infon>
        <location offset="778" length="26"/>
        <text>impaired glucose tolerance</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D006073</infon>
        <infon key="type">Disease</infon>
        <location offset="826" length="4"/>
        <text>gout</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D011928</infon>
        <infon key="type">Disease</infon>
        <location offset="885" length="20"/>
        <text>Raynaud's phenomenon</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D004417</infon>
        <infon key="type">Disease</infon>
        <location offset="910" length="8"/>
        <text>dyspnoea</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D003316</infon>
        <infon key="type">Disease</infon>
        <location offset="959" length="15"/>
        <text>corneal disease</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>6127992</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>97</offset>
      <text>Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs. This clinical picture resolved completely with cessation of the combined therapy. Baseline left ventricular function, assessed by cardiac catheterisation or nuclear angiography, was normal in two patients and only mildly reduced in the other. Simultaneously administration of beta-adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D017202</infon>
        <infon key="type">Disease</infon>
        <location offset="117" length="23"/>
        <text>ischaemic heart disease</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D006333</infon>
        <infon key="type">Disease</infon>
        <location offset="160" length="15"/>
        <text>cardiac failure</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D007022</infon>
        <infon key="type">Disease</infon>
        <location offset="177" length="11"/>
        <text>hypotension</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D001919</infon>
        <infon key="type">Disease</infon>
        <location offset="193" length="11"/>
        <text>bradycardia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>6229975</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Changes in heart size during long-term timolol treatment after myocardial infarction.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D009203</infon>
        <infon key="type">Disease</infon>
        <location offset="63" length="21"/>
        <text>myocardial infarction</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>86</offset>
      <text>The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115). The follow-up period was 12 months. The timolol-treated patients showed a small but significant increase in heart size from baseline in contrast to a decrease in the placebo group. These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume. The timolol-related increase in heart size was observed only in patients with normal and borderline heart size. In patients with cardiomegaly, the increase in heart size was similar in both groups. After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D009203</infon>
        <infon key="type">Disease</infon>
        <location offset="148" length="21"/>
        <text>myocardial infarction</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D001919</infon>
        <infon key="type">Disease</infon>
        <location offset="500" length="11"/>
        <text>bradycardia</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D006332</infon>
        <infon key="type">Disease</infon>
        <location offset="694" length="12"/>
        <text>cardiomegaly</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D007238</infon>
        <infon key="type">Disease</infon>
        <location offset="772" length="10"/>
        <text>infarction</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>6634932</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>79</offset>
      <text>UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias. Both anti-arrhythmic efficacy and bioavailability were compared to oral drug. Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs. The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D017180</infon>
        <infon key="type">Disease</infon>
        <location offset="207" length="24"/>
        <text>ventricular tachycardias</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D017180</infon>
        <infon key="type">Disease</infon>
        <location offset="339" length="23"/>
        <text>ventricular tachycardia</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>6892185</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.</text>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>99</offset>
      <text>The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated. Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine. On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride. It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D015878</infon>
        <infon key="type">Disease</infon>
        <location offset="332" length="9"/>
        <text>mydriasis</text>
      </annotation>
      <annotation id="1">
        <infon key="identifier">MESH:D014202</infon>
        <infon key="type">Disease</infon>
        <location offset="343" length="6"/>
        <text>tremor</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D004830</infon>
        <infon key="type">Disease</infon>
        <location offset="354" length="24"/>
        <text>clonic-tonic convulsions</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D015878</infon>
        <infon key="type">Disease</infon>
        <location offset="587" length="9"/>
        <text>mydriasis</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D014202</infon>
        <infon key="type">Disease</infon>
        <location offset="598" length="6"/>
        <text>tremor</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D004830</infon>
        <infon key="type">Disease</infon>
        <location offset="609" length="24"/>
        <text>clonic-tonic convulsions</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D015878</infon>
        <infon key="type">Disease</infon>
        <location offset="841" length="9"/>
        <text>mydriasis</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D014202</infon>
        <infon key="type">Disease</infon>
        <location offset="852" length="6"/>
        <text>tremor</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D004830</infon>
        <infon key="type">Disease</infon>
        <location offset="863" length="24"/>
        <text>clonic-tonic convulsions</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>8888541</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Serotonin syndrome from venlafaxine-tranylcypromine interaction.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D020230</infon>
        <infon key="type">Disease</infon>
        <location offset="0" length="18"/>
        <text>Serotonin syndrome</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>65</offset>
      <text>Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine. We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis. His pupils were 7 mm and sluggishly reactive to light. Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws. He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity. His subsequent course was remarkable for non-immune thrombocytopenia which resolved. The patient's maximal temperature was 101.2 F and his CPK remained &lt; 500 units/L with no other evidence of rhabdomyolysis. His mental status normalized and he was transferred to a psychiatry ward. This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="182" length="15"/>
        <text>muscle rigidity</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D012798</infon>
        <infon key="type">Disease</infon>
        <location offset="199" length="10"/>
        <text>salivation</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D003221</infon>
        <infon key="type">Disease</infon>
        <location offset="211" length="9"/>
        <text>confusion</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D011595</infon>
        <infon key="type">Disease</infon>
        <location offset="222" length="9"/>
        <text>agitation</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D005334</infon>
        <infon key="type">Disease</infon>
        <location offset="236" length="12"/>
        <text>hyperthermia</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D020230</infon>
        <infon key="type">Disease</infon>
        <location offset="561" length="18"/>
        <text>serotonin syndrome</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D003866</infon>
        <infon key="type">Disease</infon>
        <location offset="634" length="10"/>
        <text>depression</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D014202</infon>
        <infon key="type">Disease</infon>
        <location offset="807" length="7"/>
        <text>tremors</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="819" length="8"/>
        <text>rigidity</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D009207</infon>
        <infon key="type">Disease</infon>
        <location offset="930" length="15"/>
        <text>myoclonic jerks</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="947" length="8"/>
        <text>rigidity</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D012798</infon>
        <infon key="type">Disease</infon>
        <location offset="957" length="10"/>
        <text>salivation</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="1211" length="15"/>
        <text>muscle rigidity</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D007040</infon>
        <infon key="type">Disease</infon>
        <location offset="1300" length="15"/>
        <text>hypoventilation</text>
      </annotation>
      <annotation id="15">
        <infon key="identifier">MESH:D010243</infon>
        <infon key="type">Disease</infon>
        <location offset="1325" length="9"/>
        <text>paralyzed</text>
      </annotation>
      <annotation id="16">
        <infon key="identifier">MESH:D009127</infon>
        <infon key="type">Disease</infon>
        <location offset="1346" length="15"/>
        <text>muscle rigidity</text>
      </annotation>
      <annotation id="17">
        <infon key="identifier">MESH:D013921</infon>
        <infon key="type">Disease</infon>
        <location offset="1415" length="16"/>
        <text>thrombocytopenia</text>
      </annotation>
      <annotation id="18">
        <infon key="identifier">MESH:D012206</infon>
        <infon key="type">Disease</infon>
        <location offset="1555" length="14"/>
        <text>rhabdomyolysis</text>
      </annotation>
      <annotation id="19">
        <infon key="identifier">MESH:D010243</infon>
        <infon key="type">Disease</infon>
        <location offset="1733" length="9"/>
        <text>paralysis</text>
      </annotation>
    </passage>
  </document>
  <document>
    <id>9514561</id>
    <passage>
      <infon key="type">title</infon>
      <offset>0</offset>
      <text>Experimental cranial pain elicited by capsaicin: a PET study.</text>
      <annotation id="0">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="21" length="4"/>
        <text>pain</text>
      </annotation>
    </passage>
    <passage>
      <infon key="type">abstract</infon>
      <offset>62</offset>
      <text>Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval. It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'. To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the migraine patients. A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve. Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum. Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state. The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.</text>
      <annotation id="1">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="141" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="2">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="221" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="3">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="252" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="4">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="344" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="5">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="397" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="6">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="471" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="7">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="567" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="8">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="687" length="7"/>
        <text>painful</text>
      </annotation>
      <annotation id="9">
        <infon key="identifier">MESH:D008881</infon>
        <infon key="type">Disease</infon>
        <location offset="980" length="8"/>
        <text>migraine</text>
      </annotation>
      <annotation id="10">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1043" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="11">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1070" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="12">
        <infon key="identifier">MESH:D010146</infon>
        <infon key="type">Disease</infon>
        <location offset="1245" length="4"/>
        <text>pain</text>
      </annotation>
      <annotation id="13">
        <infon key="identifier">MESH:D006261</infon>
        <infon key="type">Disease</infon>
        <location offset="1293" length="8"/>
        <text>headache</text>
      </annotation>
      <annotation id="14">
        <infon key="identifier">MESH:D003027</infon>
        <infon key="type">Disease</infon>
        <location offset="1323" length="16"/>
        <text>cluster headache</text>
      </annotation>
    </passage>
  </document>
</collection>
